Brief: Arch Biopartners Completes Pre-IND Meeting With FDA On LSALT Peptide
08/05/2018 14:39
May 8 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS COMPLETES PRE-IND MEETING WITH U.S. FDA
ON
LSALT PEPTIDE FOR PREVENTING ACUTE KIDNEY INJURY IN CARDIAC
SURGERY PATIENTS
Source text for Eikon: ID:nGNX8Sm5C1
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide